These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

227 related articles for article (PubMed ID: 18792035)

  • 1. Benzimidazolium salts as small, nonpeptidic and BBB-permeable human prolyl oligopeptidase inhibitors.
    Tarragó T; Masdeu C; Gómez E; Isambert N; Lavilla R; Giralt E
    ChemMedChem; 2008 Oct; 3(10):1558-65. PubMed ID: 18792035
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Baicalin, a prodrug able to reach the CNS, is a prolyl oligopeptidase inhibitor.
    Tarragó T; Kichik N; Claasen B; Prades R; Teixidó M; Giralt E
    Bioorg Med Chem; 2008 Aug; 16(15):7516-24. PubMed ID: 18650094
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The natural product berberine is a human prolyl oligopeptidase inhibitor.
    Tarrago T; Kichik N; Seguí J; Giralt E
    ChemMedChem; 2007 Mar; 2(3):354-9. PubMed ID: 17295371
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Synthesis and structure-activity relationship of N-acyl-Gly-, N-acyl-Sar- and N-blocked-boroPro inhibitors of FAP, DPP4, and POP.
    Tran T; Quan C; Edosada CY; Mayeda M; Wiesmann C; Sutherlin D; Wolf BB
    Bioorg Med Chem Lett; 2007 Mar; 17(5):1438-42. PubMed ID: 17174090
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A cyclopent-2-enecarbonyl group mimics proline at the P2 position of prolyl oligopeptidase inhibitors.
    Jarho EM; Venäläinen JI; Huuskonen J; Christiaans JA; Garcia-Horsman JA; Forsberg MM; Järvinen T; Gynther J; Männistö PT; Wallén EA
    J Med Chem; 2004 Nov; 47(23):5605-7. PubMed ID: 15509157
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Simultaneous (19)F NMR screening of prolyl oligopeptidase and dipeptidyl peptidase IV inhibitors.
    Kichik N; Tarragó T; Giralt E
    Chembiochem; 2010 May; 11(8):1115-9. PubMed ID: 20397181
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Identification by 19F NMR of traditional Chinese medicinal plants possessing prolyl oligopeptidase inhibitory activity.
    Tarragó T; Frutos S; Rodriguez-Mias RA; Giralt E
    Chembiochem; 2006 May; 7(5):827-33. PubMed ID: 16628753
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A new side opening on prolyl oligopeptidase revealed by electron microscopy.
    Tarragó T; Martín-Benito J; Sabidó E; Claasen B; Madurga S; Gairí M; Valpuesta JM; Giralt E
    FEBS Lett; 2009 Oct; 583(20):3344-8. PubMed ID: 19782684
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inhibition of prolyl oligopeptidase with a synthetic unnatural dipeptide.
    Racys DT; Rea D; Fülöp V; Wills M
    Bioorg Med Chem; 2010 Jul; 18(13):4775-82. PubMed ID: 20627594
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pyrrolidinyl pyridone and pyrazinone analogues as potent inhibitors of prolyl oligopeptidase (POP).
    Haffner CD; Diaz CJ; Miller AB; Reid RA; Madauss KP; Hassell A; Hanlon MH; Porter DJ; Becherer JD; Carter LH
    Bioorg Med Chem Lett; 2008 Aug; 18(15):4360-3. PubMed ID: 18606544
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeted Covalent Inhibition of Prolyl Oligopeptidase (POP): Discovery of Sulfonylfluoride Peptidomimetics.
    Guardiola S; Prades R; Mendieta L; Brouwer AJ; Streefkerk J; Nevola L; Tarragó T; Liskamp RMJ; Giralt E
    Cell Chem Biol; 2018 Aug; 25(8):1031-1037.e4. PubMed ID: 29779956
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dipeptide proline diphenyl phosphonates are potent, irreversible inhibitors of seprase (FAPalpha).
    Gilmore BF; Lynas JF; Scott CJ; McGoohan C; Martin L; Walker B
    Biochem Biophys Res Commun; 2006 Jul; 346(2):436-46. PubMed ID: 16769036
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prolyl oligopeptidase and its role in the organism: attention to the most promising and clinically relevant inhibitors.
    Babkova K; Korabecny J; Soukup O; Nepovimova E; Jun D; Kuca K
    Future Med Chem; 2017 Jun; 9(10):1015-1038. PubMed ID: 28632451
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Binding kinetics and duration of in vivo action of novel prolyl oligopeptidase inhibitors.
    Venäläinen JI; Garcia-Horsman JA; Forsberg MM; Jalkanen A; Wallén EA; Jarho EM; Christiaans JA; Gynther J; Männistö PT
    Biochem Pharmacol; 2006 Feb; 71(5):683-92. PubMed ID: 16405869
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dicarboxylic acid azacycle l-prolyl-pyrrolidine amides as prolyl oligopeptidase inhibitors and three-dimensional quantitative structure-activity relationship of the enzyme-inhibitor interactions.
    Jarho EM; Wallén EA; Christiaans JA; Forsberg MM; Venäläinen JI; Männistö PT; Gynther J; Poso A
    J Med Chem; 2005 Jul; 48(15):4772-82. PubMed ID: 16033257
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Constrained peptidomimetics reveal detailed geometric requirements of covalent prolyl oligopeptidase inhibitors.
    Lawandi J; Toumieux S; Seyer V; Campbell P; Thielges S; Juillerat-Jeanneret L; Moitessier N
    J Med Chem; 2009 Nov; 52(21):6672-84. PubMed ID: 19888757
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Slow-binding inhibitors of prolyl oligopeptidase with different functional groups at the P1 site.
    Venäläinen JI; Juvonen RO; Garcia-Horsman JA; Wallén EA; Christiaans JA; Jarho EM; Gynther J; Männistö PT
    Biochem J; 2004 Sep; 382(Pt 3):1003-8. PubMed ID: 15217351
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prolyl oligopeptidase: a potential target for the treatment of cognitive disorders.
    Männisto PT; Venäläinen J; Jalkanen A; García-Horsman JA
    Drug News Perspect; 2007 Jun; 20(5):293-305. PubMed ID: 17878957
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Low molecular weight inhibitors of Prolyl Oligopeptidase: a review of compounds patented from 2003 to 2010.
    López A; Tarragó T; Giralt E
    Expert Opin Ther Pat; 2011 Jul; 21(7):1023-44. PubMed ID: 21539473
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Investigation of novel chemical scaffolds targeting prolyl oligopeptidase for neurological therapeutics.
    Kumar R; Parameswaran S; Bavi R; Baek A; Son M; Rampogu S; Park C; Lee G; Zeb A; Parate S; Rana RM; Lee KW
    J Mol Graph Model; 2019 May; 88():92-103. PubMed ID: 30665156
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.